TriSalus Life Sciences (TLSI) Accumulated Expenses (2020 - 2026)

TriSalus Life Sciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 15.9% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 15.9% YoY), while the FY2025 annual figure was $8.1 million, up 10.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $7.1 million, down from $8.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.4 million in Q1 2024, with the low at $6.4 million in Q4 2022.
• The 5-year median for Accumulated Expenses is $7.6 million (2024), against an average of $8.1 million.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 65.53% in 2023, then tumbled 30.32% in 2024.
• TriSalus Life Sciences' Accumulated Expenses stood at $6.4 million in 2022, then soared by 65.53% to $10.6 million in 2023, then tumbled by 30.32% to $7.4 million in 2024, then climbed by 10.07% to $8.1 million in 2025, then fell by 12.71% to $7.1 million in 2026.
• Business Quant data shows TLSI's Accumulated Expenses at $7.1 million in Q1 2026, $8.1 million in Q4 2025, and $6.8 million in Q3 2025.